XORTX Therapeutics Inc. (XRTX)
About XORTX Therapeutics Inc. (XRTX)
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
- 3
- 2018
- XNAS
90-Day SEC Filing Activity
No Form 4 activity for XRTX in the last 90 days.
XRTX Insider Transactions (Form 4)
0No Form 4 filings for XRTX yet.
Transactions appear here automatically as insiders file with the SEC.
XRTX Insider Trading - FAQ
Where can I see XRTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page tracks XRTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow XRTX insider buys?
Create a free InsiderAlpha account and press Watch on this page to add XRTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity
Related Companies - Recent Insider Activity
Learn More
- What is SEC Form 4?
- The filing insiders must submit within two business days of a trade, and how to read its transaction codes.
- Insider activity in Health Care
- Where XRTX's peers are being bought and sold.
- Every recent Form 4
- The full market-wide feed, updated as filings arrive from SEC EDGAR.
Track XRTX insider activity as it files
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
